The Canadian cannabis industry has developed into a leader in cannabis used for medicinal purposes, and the Canadian capital markets have supported its development by providing readily available sources of capital to industry players.
With the imminent legalisation of cannabis for recreational purposes, the use of cannabis in everyday life raises legal questions about its regulation and potential health and other risks. It has also created additional opportunities for capital raising in Canada by Canadian and international participants, as well as significant opportunities for M&A activity across the industry.
This webinar will canvass the following topics:
The speakers for this webinar will be John Sabetti and Ingrid VanderElst of Fasken Martineau DuMoulin LLP.
John Sabetti is a partner of the Canadian law firm Fasken Martineau and a member of the securities and M&A group’s steering committee. He practises primarily in the areas of securities, M&A and corporate commercial law. As the Canadian cannabis industry has evolved, he has been involved in structuring and implementing the go-public and capital-raising transactions, and stock exchange listings, of numerous issuers, both Canadian and foreign. He has also been involved in raising capital for ancillary businesses that provide products to the cannabis industry, including issuers that provide cannabis stream financing. In addition, as the Canadian cannabis sector has experienced recent consolidation, he has been involved in various aspects of certain M&A transactions. His clients in the cannabis sector range from industry players to many of the prominent Canadian investment banks that have taken lead roles in the sector. He is recognised by various legal industry publications as a leading lawyer for capital markets and M&A.
Ingrid VanderElst is co-chair of the Ontario region’s life sciences group of Fasken Martineau. Regularly assisting clients in the health products and related service industries, she advises on regulatory and IP issues. Clients include pharmaceutical, natural health product, medical device, cosmetic and food manufacturers, as well as pharmacy and laboratory services providers and agri-business operators including participants in the cannabis industry.
She has considerable expertise in relation to Health Canada’s regulatory regime respecting cannabis. She has advised applicants for licences as licensed producers under the Access to Cannabis for Medical Purposes Regulations and as licensed dealers under the Narcotic Control Regulations and, most recently, has been advising interested parties on the new rules under the Cannabis Act and the Cannabis Regulations to come into force in October 2018. She is also assisting a broad range of others engaged in the cannabis sector, including lenders, private equity and other investors, investment bankers, suppliers and other service providers, both Canadian and foreign parties. She holds a PhD in genetics.